Compare
Nika Pharmaceuticals, Inc vs CNBX Pharmaceuticals Inc. vs Skinvisible, Inc. vs Bioadaptives, Inc.
| Latest fiscal year | Nika Pharmaceuticals, Inc NIKA | CNBX Pharmaceuticals Inc. CNBX | Skinvisible, Inc. SKVI | Bioadaptives, Inc. BDPT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-08-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | $20.0K | $18.3K |
| Revenue growth (YoY) | n/a | -100.0% | 0.0% | +44.3% |
| Gross margin | n/a | n/a | 100.0% | 68.4% |
| Operating margin | n/a | n/a | n/m | n/m |
| Net margin | n/a | n/a | n/m | n/m |
| Net income | -$76.4K | -$314.0K | -$1.06M | -$1.56M |
| EPS (Diluted) | $0.00 | $0.00 | n/a | -$0.15 |
| Operating cash flow | -$79.7K | -$171.3K | -$38.4K | -$516.0K |
| Free cash flow | n/a | n/a | -$42.5K | -$534.0K |
| Cash & equivalents | $1.9K | $15.1K | n/a | $215.2K |
| Total assets | $21.0K | $18.4K | $127.6K | $225.9K |
| Total liabilities | $318.6K | n/a | $10.39M | $2.36M |
| Shareholders' equity | -$297.6K | -$2.50M | -$10.26M | -$2.13M |
| Return on year-end equity | n/a | n/a | n/a | n/a |
| Shares outstanding | 1.05B | 553.96M | 5.40M | 12.01M |
Revenue, most recent five fiscal years
| Fiscal year | Nika Pharmaceuticals, Inc | CNBX Pharmaceuticals Inc. | Skinvisible, Inc. | Bioadaptives, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2024-12-31 | $0 Ended 2025-08-31 | $20.0K Ended 2025-12-31 | $18.3K Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2023-12-31 | $130.1K Ended 2024-08-31 | $20.0K Ended 2024-12-31 | $12.7K Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2022-12-31 | $410.2K Ended 2023-08-31 | $20.0K Ended 2023-12-31 | $28.6K Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2021-12-31 | $30.0K Ended 2022-08-31 | $279.3K Ended 2022-12-31 | $17.2K Ended 2022-12-31 |
| 4 years earlier | n/a | $0 Ended 2021-08-31 | $663.4K Ended 2021-12-31 | $19.8K Ended 2021-12-31 |